Skip to main content
Title
Associate Research Professor
Area of Study/Expertise
Pharmacoepidemiology, Medical Device Epidemiology and Surveillance, Real-World Evidence
Email
mer256@ifh.rutgers.edu

Mary Beth Ritchey, PhD

Faculty

About
Mary Beth Ritchey is a part-time Associate Research Professor at PETS where she conducts pharmacoepidemiology research, teaches, and mentors students/fellows in pharmacoepidemiology methodology. Outside of PETS, she is the Principal and Owner of Med Tech Epi, LLC where she conducts strategic evidence generation planning and analysis of health care databases for regulatory decision-making under contract with pharmaceutical and medical device clients. 

Dr. Ritchey is an innovative and dynamic epidemiologist with over 15 years “real-world evidence” observational research experience across government, industry, and academia in study design and implementation. She is adept with scientific, technical, and logistical aspects of conducting regulatory-grade feasibility, utilization, safety, and effectiveness studies of medical products. Dr. Ritchey is experienced leading international multi-stakeholder teams for research, strategic planning and coordination of scientific programming, agenda-setting, and decision-making. She has proficiency in garnering efficiency in a continuous learning environment, specifically medical product safety and real-world evidence, through review of research processes and clarification of stakeholder needs.

Dr. Ritchey is a Fellow of in the International Society of Pharmacoepidemiology (ISPE), Associate Editor for Pharmacoepidemiology and Drug Safety (PDS) and serves on the Executive Operations and Scientific Oversight Committees for the Medical Device Epidemiology Network (MDEpiNet)
public private partnership with FDA.

Research Profile
Pharmacoepidemiology, Health Outcomes, Medical Device Epidemiology and Surveillance, Rare Disease, Real-World Evidence, Integrated Evidence Planning and Generation

Select Publications

  1. Ritchey ME, Girman C. Evaluating the feasibility of electronic health records and claims data sources for specific research purposes. Therapeutic Innovation & Reg Sci. 2020. PMID: 33258098
  2. Ritchey ME, West SL, Maldonado G. Validity of Pharmacoepidemiologic Drug and Diagnosis Data. In Strom B, Hennesey S, Kimmel S. Pharmacoepidemiology, 6th ed. Wiley. 2019; 948-90.
  3. Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, et al. Cardiovascular safety during and after use of phentermine and topiramate. J Clin Endocrinol Metab. 2019;104(2):513-22. PMID: 30247575
  4. Anthony MS, Armstrong MA, Getahun D, Scholes D, Gatz J, …, Ritchey ME, et al. Identification and validation of uterine perforation, intrauterine device expulsion, and breastfeeding in four health care systems with electronic health records. Clinical Epidemiol. 2019; 11:635-43. PMID: 31413641
  5. Brodovicz KG, Chen Y, Liu Z, Ritchey ME, Liao J, Engel SS. Characterization of Sitagliptinp Use in Patients with type 2 diabetes and chronic kidney diease by cross-sectional analysis of a medical insurance claims database. Diabetes Ther. 2015;6(4):627-634. PMID: 26438107
  6. Jalbert JJ, Ritchey ME, Mi X, Chen CY, Hammill BG, Curtis LH, Setoguchi S. Methodological considerations in observational comparative effectiveness research in implantable medical devices: an epidemiological perspective. Am J Epidemiol. 2014; 180(9):949-58. PMID: 25255810

Grants
September 2019 – August 2021
Data Analysis for Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) Study
NIH/NIA (75N95019C00057)
Subcontract Co-Investigator

July 2019 – February 2024
Strengthening the Evidence-Base for Drug-Disease Interactions in Older Adults
NIH/NIA (R01AG061092-01A1)
Co-Investigator